Neuraxis Inc.

Company Overview

Business Model: Neuraxis, Inc. is a medical technology company focused on developing neuromodulation therapies for chronic and debilitating conditions in children and adults. The company's core technology is Percutaneous Electrical Nerve Field Stimulation (PENFS), developed internally. Primary revenue is generated from the sale of its IB-Stim device to healthcare companies, predominantly hospitals and clinics. Neuraxis, Inc. also markets the Rectal Expulsion Device (RED) and has licensed its NSS-2 Bridge device to Masimo Corporation.

Market Position: Neuraxis, Inc. holds a first-to-market position with its IB-Stim device, which is the only medical therapy with US FDA clearance for pediatric Irritable Bowel Syndrome (IBS) that has demonstrated improvement in pain, global symptoms, and functional disability, and proven superior to placebo in a randomized controlled trial. The total addressable market for IB-Stim is estimated at up to 6 million children. The company has sold IB-Stim to approximately 77 out of 260 target children's hospitals in the United States. The RED device addresses an unmet clinical need for an efficient, accurate, and cost-effective office-based anorectal function test for chronic constipation in adults. Competitive strengths include a strong portfolio of device and method patents, academic society support, and robust clinical data.

Recent Strategic Developments:

• Initial Public Offering (IPO): On August 9, 2023, Neuraxis, Inc. completed an IPO, selling 1,098,667 shares of common stock at $6.00 per share, generating net proceeds of $4,110,721.
• Product Launches/Clearances: The Rectal Expulsion Device (RED) received US FDA clearance (K242304) in 2024.
• Capital Structure Changes: On August 15, 2024, shareholders authorized 5,000,000 shares of preferred stock, designating 4,000,000 as Series B Preferred Stock with an 8.5% cumulative dividend rate. Series A and Series Seed Preferred Stock were retired. On November 11, 2024, the Series B Preferred Stock designation was increased to 5,000,000 shares, and the dividend period extended to December 31, 2026.
• Reimbursement & Market Access: In 2023, Neuraxis, Inc. launched an internal Prior Authorization team to streamline patient access to IB-Stim. In September 2024, the American Medical Association's CPT Editorial Panel accepted a Category I CPT Code (placeholder 64X11) for PENFS, effective January 1, 2026, replacing the Category III CPT Code (0720T). Sixteen commercial health insurers, covering approximately 45,000,000 lives, have instituted formal medical policy coverage for PENFS, with an additional insurer covering approximately 6,000,000 members expected in Q2 2025.

Geographic Footprint: Neuraxis, Inc.'s corporate headquarters are in Carmel, Indiana, with additional office space leased in Versailles, Indiana. All of the company's sales are to customers located within the United States. Key markets for the IB-Stim device are children's hospitals and pediatric clinics across the United States.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin (2024): 86.5% (vs. 87.7% in 2023)
• Operating Margin (2024): -266.4% (vs. -270.9% in 2023)
• Net Margin (2024): -306.8% (vs. -594.6% in 2023)

Investment in Growth:

• R&D Expenditure (2024): $206,107 (7.7% of revenue)
• R&D Expenditure (2023): $169,315 (6.9% of revenue)
• Capital Expenditures (2024): $27,776
• Capital Expenditures (2023): $71,781
• Strategic Investments: R&D expenses in 2024 included costs to bring the RED product to market and higher costs on a medical research project. The company is also conducting additional clinical trials for its PENFS technology in multiple pediatric conditions, including functional nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome.

Business Segment Analysis

IB-Stim

Financial Performance:

• Revenue (2024): $2,685,925 (+9.2% YoY)
• Operating Margin: Not separately disclosed, but the segment contributes to the overall company gross margin of 86.5% in 2024.
• Key Growth Drivers: Revenue growth was primarily driven by volume increases from financial assistance programs offering discounts to uninsured patients. Future growth is anticipated from broader insurer acceptance and the upcoming Category I CPT Code for PENFS.

Product Portfolio:

• IB-Stim is a PENFS system indicated for patients 8-21 years of age with functional abdominal pain associated with IBS.
• The device is intended for use 120 hours per week, one device per week, for four consecutive weeks.
• Studies have demonstrated significant improvement in pain, disability, and global symptoms with no serious adverse events.

Market Dynamics:

• Competitive positioning: IB-Stim is the only FDA-cleared medical therapy for pediatric IBS, offering a non-drug alternative.
• Key customer types: Children's hospitals and pediatric clinics.
• Market trends: Addresses a significant unmet need in the pediatric population due to limited effective and safe treatment options for functional abdominal pain disorders.

Rectal Expulsion Device (RED)

Financial Performance:

• Revenue: Not separately disclosed. R&D costs were incurred in 2024 to bring the product to market.
• Operating Margin: Not separately disclosed.
• Key Growth Drivers: RED addresses a clinical need for an easy-to-use, office-based, point-of-care anorectal function test for chronic constipation in adults. It helps identify patients who may benefit from pelvic floor therapy.
• Reimbursement: Billable under CPT 91120.

Product Portfolio:

• RED is indicated to evaluate neuromuscular function and rectal hypersensitivity in adult patients with chronic constipation.
• It functions as a self-inflating expulsion device and a balloon to assess rectal hypersensitivity.

Market Dynamics:

• Competitive positioning: Designed to be efficient, accurate, and cost-effective, aiming to increase the low percentage of constipation patients currently undergoing anorectal testing.
• Key customer types: Gastroenterology practices.
• Market trends: Chronic constipation affects 10-15% of the North American population, with approximately 40% of patients not responding to conventional laxative therapy.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not mentioned in the filing.
• Dividend Payments:
  • Common Stock: Neuraxis, Inc. has not declared or paid cash dividends on its common stock and does not anticipate doing so in the foreseeable future, intending to reinvest future earnings into business development.
  • Series B Preferred Stock: Undeclared cumulative dividends totaled $211,268 as of December 31, 2024. Dividends accrue at 8.5% per annum, payable quarterly in cash or common stock at the company's discretion through December 31, 2026.
• Dividend Yield: Not applicable for common stock.
• Future Capital Return Commitments: No specific future capital return commitments beyond the Series B Preferred Stock dividends were disclosed.

Balance Sheet Position:

• Cash and Equivalents (2024): $3,696,870
• Cash and Equivalents (2023): $78,560
• Total Debt (2024): $154,152 (current portion of notes payable)
• Total Debt (2023): $148,062 (current portion of notes payable)
• Net Cash Position (2024): $3,542,718
• Net Cash Position (2023): $(69,502)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: As of December 31, 2024, short-term notes payable include a $210,000 promissory note (7.40% interest) maturing June 9, 2025, and a $64,328 promissory note (7.65% interest) maturing September 1, 2025. The principal balance of $4,935,000 from the 2024 Convertible Notes was mandatorily converted into Series B Preferred Shares on August 15, 2024.

Cash Flow Generation:

• Operating Cash Flow (2024): $(6,098,264)
• Operating Cash Flow (2023): $(6,693,978)
• Free Cash Flow (2024): $(6,126,040) (Operating Cash Flow - Capital Expenditures)
• Free Cash Flow (2023): $(6,765,759) (Operating Cash Flow - Capital Expenditures)
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: Neuraxis, Inc. relies on a sole third-party manufacturer, GMI Corporation, for the production of its IB-Stim device. GMI Corporation operates a 69,000 square foot facility in Indiana, with approximately 1,000 square feet dedicated to Neuraxis, Inc. products. GMI Corporation maintains ISO 13485:2016 certification, FDA registration, and ITAR registration, ensuring adherence to stringent quality standards. Medical providers undergo IB-Stim Training and Certification to properly place the device in outpatient clinics, with removal possible by either the provider or the patient at home.

Supply Chain Architecture: Key Suppliers & Partners:

• Manufacturing Partner: GMI Corporation - Sole manufacturer for the IB-Stim device. Neuraxis, Inc. provides necessary equipment and retains ownership, while GMI Corporation assumes risk of loss or damage to equipment and consigned materials.
• Technology Partner: TKBMN, LLC - Neuraxis, Inc. holds an exclusive, worldwide, royalty-free license for the auricular portion of certain patent rights from TKBMN, LLC for electro-therapy treatment. Neuraxis, Inc. is responsible for associated patent maintenance and prosecution fees.
• Licensing Partner: Masimo Corporation - Holds an exclusive, fully paid-up, royalty-free license for the NSS-2 Bridge device and its associated trademark. Neuraxis, Inc. received a one-time licensing fee of $250,000 from Masimo Corporation and will not receive further revenue from this product.

Facility Network:

• Manufacturing: GMI Corporation's facility in Indiana.
• Research & Development: Clinical trials are conducted at various children's hospitals, including Children’s Wisconsin/Medical College of Wisconsin and Children’s Hospital of Orange County.
• Distribution: Products are sold to healthcare customers, primarily hospitals and clinics, within the United States.

Operational Metrics:

• Capacity utilization: GMI Corporation's kit production capacity is sufficient for all projected needs.
• Efficiency measures: Not explicitly disclosed.
• Quality indicators: GMI Corporation's quality management system is ISO 13485:2016 certified, FDA registered, and ITAR registered.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Neuraxis, Inc. utilizes a direct sales force to market its products.
• Digital Platforms: Marketing efforts include search engine optimization (SEO) and other internet channels.
• Channel Partners: Not explicitly detailed for IB-Stim or RED, but Masimo Corporation serves as a licensee for the NSS-2 Bridge device.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Children's hospitals are primary customers for the IB-Stim device. Neuraxis, Inc. has sold IB-Stim to approximately 77 children's hospitals in the United States.
• Customer Concentration:
  • In 2024, the top three customers accounted for approximately 40% of total sales.
  • In 2023, the top three customers accounted for approximately 45% of total sales.
  • Specific customer revenue contributions in 2024: Customer A (20%), Customer B (15%), Customer C (5%).
  • Accounts receivable concentration in 2024: Customer A (49%), Customer C (9%).

Geographic Revenue Distribution:

• California: 29.0% of total revenue in 2024 (24.4% in 2023).
• Ohio: 16.1% of total revenue in 2024 (16.6% in 2023).
• Illinois: 9.2% of total revenue in 2024 (4.8% in 2023).
• Wisconsin: 5.9% of total revenue in 2024 (11.9% in 2023).
• Massachusetts: 5.7% of total revenue in 2024 (5.2% in 2023).
• Florida: 5.6% of total revenue in 2024 (7.6% in 2023).
• All other states: 28.6% of total revenue in 2024 (29.5% in 2023).
• Growth Markets: The company's strategic focus is on opportunities within the pediatrics industry in the United States.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The pediatrics industry presents multi-billion-dollar market opportunities, particularly in addressing chronic and debilitating conditions where research and therapeutics are often lacking. The total addressable market for IB-Stim in children with functional abdominal pain associated with IBS is estimated at up to 6 million. The neurostimulation market is evolving, with increasing recognition of neuromodulation as a scientifically supported approach to treating neurological conditions.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Off-label drugs and drugs with adult-only FDA approval for IBS: These include Rifaximin, Amitiza, Linzess, Plecanatide, and Eluxadoline. These often carry FDA black box labels and lack evidence for efficacy or safety in pediatric populations.
• Psychological treatments: Cognitive Behavioral Therapy (CBT) or guided imagery are effective but face limitations in access to trained therapists and require longer treatment durations (8-12 weeks).
• Other neurostimulation devices: Devices like gammaCore (cleared for cluster/migraine headaches), Transcranial Magnetic Stimulation (cleared for major depressive disorder/OCD), and Roo System/Sparrow therapy system (cleared for opioid withdrawal) are not specifically cleared or supported by data for functional bowel disorders or IBS.

Emerging Competitive Threats:

• New entrants and disruptive technologies in the non-implanted neurostimulation space are expected to grow.
• Digital therapeutics and virtual reality solutions for IBS, primarily targeting adults, could emerge as future competitors.

Competitive Response Strategy: Neuraxis, Inc. aims to maintain its competitive advantage by leveraging its first-to-market status for pediatric IBS, expanding its pipeline into additional pediatric indications using its PENFS technology, and protecting its strong patent portfolio. The company is actively working to secure broader insurance coverage and favorable CPT codes, and utilizes a direct sales force to target children's hospitals and pediatric clinics.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The company faces risks related to market acceptance of its new technologies, as physicians may be reluctant to prescribe without extensive experience or additional data. The market size for its products may be smaller than estimated. Competition from existing and new therapies, including those from larger companies with greater resources, could impact market share. The evolving regulatory landscape for electrical treatments and potential changes in treatment standards pose ongoing challenges. Technology Disruption: The company's success depends on adapting its technology to user requirements and emerging treatment standards. Failure to do so, or the development of competing technologies by others, could render its products uncompetitive or obsolete. Customer Concentration: Not explicitly detailed as a specific risk, but the company's sales are concentrated in a few key customers (top 3 customers accounted for 40% of sales in 2024).

Operational & Execution Risks

Supply Chain Vulnerabilities: Neuraxis, Inc. relies on single-source suppliers for some components and a sole manufacturer (GMI Corporation) for its IB-Stim device. Any disruption, quality control issues, or failure of these suppliers could interrupt manufacturing, delay clinical studies, and harm the business. Switching suppliers would entail additional regulatory delays and costs. Capacity Constraints: While GMI Corporation currently has sufficient capacity, anticipated growth could strain supplier capabilities, requiring careful monitoring and scaling of quality assurance programs.

Financial & Regulatory Risks

Market & Financial Risks: Neuraxis, Inc. has a history of substantial operating losses and anticipates continued losses due to R&D and commercialization efforts. Its ability to achieve profitability and fund operations depends on widespread insurance coverage and additional FDA clearances. Product liability suits, whether meritorious or not, could result in significant costs, reputational damage, and increased insurance rates. Regulatory & Compliance Risks: The company's products are subject to extensive and evolving regulation by the US FDA and comparable foreign authorities. Failure to comply with ongoing requirements (e.g., QSR, MDR, CE Mark, QMS Ordinance in Japan) or obtain new clearances for product modifications or new indications could lead to sanctions, recalls, and significant fines. Promotion of unapproved or off-label uses could also result in penalties. Compliance with healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act, Sunshine Act) and data privacy laws (e.g., HIPAA, GDPR) is critical, with potential for severe penalties for violations. Clinical trials face risks of delays, termination, or inconclusive results due to patient enrollment difficulties, adverse events, or non-compliance with good clinical practices.

Geopolitical & External Risks

Geopolitical Exposure: Not explicitly detailed beyond general adverse global economic conditions. Trade Relations: Not explicitly detailed. Sanctions & Export Controls: Not explicitly detailed.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas: Neuraxis, Inc.'s R&D is centered on neuromodulation therapies, specifically its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. This technology targets brain areas that process pain by sending gentle electrical impulses into cranial nerve bundles in the ear. Innovation Pipeline: The company has an active pipeline focused on pediatric conditions, leveraging its PENFS technology.

• Functional dyspepsia (nausea): Randomized Controlled Trial (RCT) completed, data being analyzed (NCT03675321).
• Post-concussion syndrome: RCT currently enrolling patients (NCT04978571).
• Chemotherapy-induced nausea and vomiting: RCT currently enrolling patients (NCT05143554).
• Cyclic vomiting syndrome: Pilot study completed (NCT03434652), with an RCT anticipated to begin enrolling in the second half of 2023.

Intellectual Property Portfolio:

• Patent Strategy: Neuraxis, Inc. holds 12 granted patents in the United States, 7 pending US patent applications, 1 granted foreign patent (Japan), and 2 pending foreign patent applications (Canada). The company's method patents specifically protect access to the brain, particularly the limbic systems, through auricular nerve branches for functional bowel disorders or IBS. Capitalized patent costs are amortized over the remaining life of the granted patent.
• Licensing Programs: The NSS-2 Bridge device was exclusively licensed to Masimo Corporation for a one-time fee of $250,000. Neuraxis, Inc. also has an exclusive, royalty-free license from TKBMN, LLC for certain auricular patent rights, for which Neuraxis, Inc. covers maintenance and prosecution fees.
• IP Litigation: The company is currently involved in an unresolved dispute with Dr. Arturo Taca, who has asserted an interest in U.S. Patent No. 10,413,719.

Technology Partnerships:

• Strategic Alliances: Collaboration with Masimo Corporation for the NSS-2 Bridge device.
• Research Collaborations: Clinical trials are conducted in collaboration with leading academic institutions such as Children’s Wisconsin/Medical College of Wisconsin and Children’s Hospital of Orange County.

Leadership & Governance

Executive Leadership Team

| Position | Executive | Tenure | Prior Experience